Small changes to the design of antibody-drug conjugate can have a dramatic effect on its structure and biological activity. Effective product characterization is essential to understanding the impact of these changes. Here we discuss methods to provide insight at critical junctures in ADC development.
There are many different design considerations facing developers of antibody-drug conjugates: these variables must be tuned to achieve the right balance of efficacy and safety. For example, the choice of linker can influence an ADC's potency, toxicity and pharmacokinetics.
In this webinar we explore the influence of various PEG linkers on the structure of a model ADC by identifying specific sites of conjugation by peptide mapping, investigating changes in higher order structure by HDX mass spectrometry, and examining the impact on binding by SPR spectroscopy.
We demonstrate that employing a range of orthogonal methods is critical to understanding the structure-function relationships of an ADC.
In this webinar, you will learn about:
- How the choice of linker can influence an ADC's activity
- Information-rich methods to probe ADC structure and function
- Effective strategies for thorough characterization of ADC products